• H Ehrén, K Palmér, M Eriksson, and B Frenckner.
• Department of Pediatric Surgery, Karolinska Institute, St. Göran's Hospital, Stockholm, Sweden.
• Acta Paediatr. 1995 Apr 1;84(4):442-6.

AbstractExtracorporeal membrane oxygenation (ECMO), which can be described as treatment with a modified heart-lung machine over a prolonged period of time, is used to support patients with life-threatening but potentially reversible lung failure. ECMO by itself does not cure the patient but gives the lungs a chance to rest while awaiting spontaneous or therapeutic healing. The method is well documented in the neonatal age group. In the non-neonatal age group, however, experience is less extensive. This report of the initial result from our hospital with 12 non-neonatal pediatric cases shows high survival and low morbidity. Nine of the 12 patients were able to be weaned from ECMO (75% survival) and 8 of these 9 patients were long-term survivors. Medium time on the ventilator after discontinuation of ECMO was 4 days. At follow-up, all long-term survivors had no signs of neurological or pulmonary sequelae. These encouraging results point to the fact that ECMO should be considered more often in cases of life-threatening but potentially reversible pulmonary failure.

12 keywords...

hide…